公开(公告)号：US20210260119A1

公开(公告)日：2021-08-26

申请号：US17205951

申请日：2021-03-18

Applicant: CUROCELL INC. ,  KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Chan Hyuk KIM ,  Young-Ho LEE ,  Yujean LEE ,  HyeongJi LEE ,  Sang Hoon LEE

IPC: A61K35/17 ,  A61P35/00 ,  A61K31/7088 ,  A61K38/17 ,  A61K39/395 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  C12N15/113

Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of a gene that weakens the function of the immune cell.

公开(公告)号：US11679129B2

公开(公告)日：2023-06-20

申请号：US16958649

申请日：2019-01-10

Applicant: CUROCELL INC. ,  KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Chan Hyuk Kim ,  Young-Ho Lee ,  Yujean Lee ,  HyeongJi Lee ,  Sang Hoon Lee

IPC: C12N15/113 ,  A61K35/17 ,  A61P35/00 ,  A61K31/7088 ,  A61K38/17 ,  A61K39/395 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  C07K14/47 ,  C12N5/0783 ,  A61K39/00

CPC classification number: A61K35/17 ,  A61K31/7088 ,  A61K38/177 ,  A61K38/1774 ,  A61K39/3955 ,  A61P35/00 ,  C07K14/4702 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/2803 ,  C12N5/0637 ,  C12N15/1138 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/5158 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/715 ,  C12N2310/122 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/31 ,  C12N2320/32 ,  C12N2510/00

Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of a gene that weakens the function of the immune cell.

公开(公告)号：US20230381236A1

公开(公告)日：2023-11-30

申请号：US18317797

申请日：2023-05-15

Applicant: CUROCELL, INC. ,  KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Chan Hyuk KIM ,  Young-Ho LEE ,  Yujean LEE ,  HyeongJi LEE ,  Sang Hoon LEE

IPC: A61K35/17 ,  A61P35/00 ,  A61K31/7088 ,  A61K38/17 ,  A61K39/395 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  C12N15/113 ,  C07K14/47 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61P35/00 ,  A61K31/7088 ,  A61K38/177 ,  A61K38/1774 ,  A61K39/3955 ,  A61K2039/505 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/2803 ,  C12N15/1138 ,  C07K14/4702 ,  C12N5/0637 ,  C07K14/7051

Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of a gene that weakens the function of the immune cell.

公开(公告)号：US20220348928A1

公开(公告)日：2022-11-03

申请号：US17626768

申请日：2020-07-16

Applicant: CUROCELL INC. ,  KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Gun Soo KIM ,  Mi Kyung KIM ,  Chan Hyuk KIM ,  Young-Ho LEE ,  HyeongJi LEE

IPC: C12N15/113 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  A61K35/17 ,  A61P35/00

Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of two genes that weaken the function of the immune cell.

公开(公告)号：US20220348871A1

公开(公告)日：2022-11-03

申请号：US17701535

申请日：2022-03-22

Applicant: CUROCELL INC. ,  KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Chan Hyuk KIM ,  Young-Ho LEE ,  Yujean LEE ,  HyeongJi LEE ,  Sang Hoon LEE ,  Sang Hoon LEE

IPC: C12N5/0783 ,  C07K14/725 ,  C07K14/47

Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of a gene that weakens the function of the immune cell.

公开(公告)号：US12285438B2

公开(公告)日：2025-04-29

申请号：US17701535

申请日：2022-03-22

Applicant: CUROCELL INC. ,  KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Chan Hyuk Kim ,  Young-Ho Lee ,  Yujean Lee ,  HyeongJi Lee ,  Sang Hoon Lee

IPC: A61K31/7088 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K14/47 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/113

Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of a gene that weakens the function of the immune cell.

公开(公告)号：US20230167184A1

公开(公告)日：2023-06-01

申请号：US17908823

申请日：2021-03-15

Applicant: CUROCELL INC. ,  EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION

Inventor： Hyunbo SHIM ,  Hyung Cheol KIM ,  Mi Kyung KIM

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K2317/565 ,  C07K2319/02 ,  C07K2319/03

Abstract: An embodiment relates to an anti-BCMA-binding protein and, more specifically, provides an isolated BCMA-binding protein comprising an antigen-binding domain that binds specifically to BCMA, wherein the antigen-binding domain comprises: i) heavy chain variable domain complementarity determining region 1 (VH-CDR1) comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 80% homology to SEQ ID NO: 1; ii) VH-CDR2 comprising the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 80% homology to SEQ ID NO: 2; and iii) VH-CDR3 comprising the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence having at least 80% homology to SEQ ID NO: 3.

公开(公告)号：US20210060067A1

公开(公告)日：2021-03-04

申请号：US16958649

申请日：2019-01-10

Applicant: CUROCELL INC. ,  KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Chan Hyuk KIM ,  Young-Ho LEE ,  Yujean LEE ,  HyeongJi LEE ,  Sang Hoon LEE

IPC: A61K35/17 ,  A61P35/00 ,  C12N15/113 ,  A61K31/7088 ,  C07K16/28 ,  A61K39/395 ,  C07K14/705 ,  C07K14/725 ,  A61K38/17

Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of a gene that weakens the function of the immune cell.